About us
About YSK Labs:
An R&D-Driven Pharmaceutical Company
At YSK Labs, we are dedicated to transforming pharmaceutical manufacturing through proprietary, in-house technology. What began with our breakthrough in Directly Compressible (DC) Granules has grown into an integrated pharmaceutical company spanning three areas: DC Granules for formulators, finished-formulation tablet manufacturing under our own brands and for third-party partners, and a nutraceutical division. Every product is built on the same foundation — a relentless R&D approach, green and sustainable technology, and an experienced scientific team. Our facility runs an annual capacity of 400–500 metric tons of DC Granules and up to 500 million finished tablets per year, all under one roof.
What are DC Granules?
DC Granules represent a breakthrough semi-formulated state of APIs. These granules revolutionize the formulation process by eliminating the need for granulation and extensive processing. In a single compression step, they seamlessly transform into solid dosage forms (tablets), reshaping the landscape of pharmaceutical manufacturing.
Benefits of DC Granules
By embracing DC Granules, formulators unlock a multitude of
invaluable benefits:
Simplified Manufacturing Process
DC Granules eliminate the need for complex granulation and drying steps, streamlining production into a single compression step.
Cost Efficiency
Reduced processing stages lead to significant cost savings in terms of equipment, energy, and resource utilization.
Time-to-Market Acceleration
The streamlined process speeds up formulation development, allowing products to reach the market faster.
Enhanced Product Quality
DC Granules ensure consistent content uniformity, accurate dosing, and reliable therapeutic outcomes.
Resource Optimization
Fewer processing steps free up production capacities, maximizing resource allocation for other critical aspects.
Innovative Formulation Possibilities
DC Granules enable the creation of novel dosage forms with enhanced solubility, dissolution, and bioavailability.
Regulatory Advantage
The simplified process can lead to quicker regulatory approvals and compliance.
Improved Patient Experience
Smaller tablet sizes achieved with DC Granules enhance patient compliance and ease of administration.
Beyond Granules:
Beyond Granules: Finished Formulation Manufacturing
Building on our DC Granule technology, YSK manufactures finished tablets and oral solid dosage forms — both as our own branded generics and as a contract manufacturing partner to pharmaceutical companies. With capacity for up to 500 million tablets per year and full IR, SR, and XR capability, all built on the same proprietary, green technology, we offer partners a single, integrated source from formulation development through to finished product.
Our
Technical Advantage
At the heart of our operations lies a technical prowess that sets us apart:
Revolutionizing Formulation
Our relentless pursuit of excellence has led to the development of an excellent DC Granule technology.
This innovation transforms the final product (tablet) in meaningful ways.
Enhancing Solubility and Dissolution
Our technology elevates solubility and dissolution performance, driving optimal drug delivery.
Optimizing Tablet Characteristics
We miniaturize tablet sizes, enhancing swallowability, and reducing excipient loads.
Cutting-Edge Production Facility
Complementing our technical prowess, YSK Labs has established a state-of-the-art facility dedicated to producing around 400-500 metric tons of DC Granules annually.
Connect With Us
Partner with YSK Labs across DC Granules, finished formulation manufacturing, and private-label development. Reach out to explore collaboration, contract manufacturing, and custom formulation solutions.
Recognitions
